Quarterly ResultJun 5, 2026, 06:31 AM
Takeda Revises FY2025 Consolidated Financial Statements
AI Summary
Takeda Pharmaceutical Co. Ltd. announced a revision to its consolidated financial statements for fiscal year 2025, which ended March 31, 2026. This revision follows a jury verdict on May 18, 2026, in the AMITIZA® (lubiprostone) antitrust litigation in the U.S. District Court for the District of Massachusetts, necessitating the recognition of provisions for legal proceedings. Despite the revisions to reported earnings, the company confirmed no changes to its Core financial results for FY2025, FY2026 financial forecast, or management guidance, and dividends remain unchanged.
Key Highlights
- Takeda revised its FY2025 consolidated financial statements due to a jury verdict in AMITIZA antitrust litigation.
- The revision includes the recognition of provisions for legal proceedings.
- No changes to FY2025 Core financial results.
- No changes to FY2026 financial forecast.
- No changes to Management Guidance.
- FY2025 year-end dividend remains JPY 100 per share.
- FY2026 annual dividend forecast remains JPY 204 per share.
Price Impact
More from TAK